Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

BACKGROUND: STRIVE is a multicenter, observational, open-label, single-arm study of natalizumab in anti–JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS). The objective of this prespecified 2-year interim analysis was to determine the effectiveness of nata...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Neurol
Главные авторы: Perumal, Jai, Fox, Robert J., Balabanov, Roumen, Balcer, Laura J., Galetta, Steven, Makh, Shavy, Santra, Sourav, Hotermans, Christophe, Lee, Lily
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2019
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555913/
https://ncbi.nlm.nih.gov/pubmed/31176355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-019-1337-z
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы